CONVERTINO, IRMA Statistiche
CONVERTINO, IRMA
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
A clinician network for sharing patients experiences in pharmacovigilance: the PHARMACOWIKILANCE project
2017-01-01 Convertino, I; Galiulo, M; Sansone, Ac; Marino, A; Knezevic, T; Pieroni, S; Blandizzi, C; Tuccori, M
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy
2018-01-01 Convertino, I; Salvadori, S; Pecori, A; Galiulo, Mt; Ferraro, S; Parrilli, M; Corona, T; Turchetti, G; Blandizzi, C; Tuccori, M
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
2021-01-01 Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M
Adverse drug reactions in oncoLogy: intEnsive monitoring program on biotechnological anD taRget therapies in Oncologic patientS-ALEXANDROS observational study
2017-01-01 Galiulo, M; Convertino, I; Blandizzi, C; Tassi, R; Diacciati, S; Nobili, S; Sansone, Ac; Marino, Aa; Mini, E; Mazzei, T; Vannacci, A; Parrilli, M; Corona, T; Tuccori, M
Allopurinol adherence among patients with gout: an Italian general practice database study
2015-01-01 Mantarro, Stefania; CAPOGROSSO SANSONE, Alice; Tuccori, Marco; Blandizzi, Corrado; Montagnani, S; Convertino, I; Antonioli, Luca; Fornai, Matteo; Cricelli, I; Pecchioli, S; Cricelli, C; Lapi, F.
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future
2021-01-01 Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D.
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study)
2021-01-01 Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M.
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
2020-01-01 Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D.
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease
2019-01-01 Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports
2019-01-01 Ferraro, S; Leonardi, L; Blandizzi, C; Convertino, I; Tuccori, M
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study
2019-01-01 Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Salvadori, S; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Riengler, S; Menditto, E; Parrilli, M; Rossi, M; Orlando, V; Pieroni, S; Vannacci, A
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study
2018-01-01 Ferraro, S; Convertino, I; Salvadori, S; Pieroni, S; Pecori, A; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Parrilli, M; Rossi, M; Vannacci, A; Blandizzi, C; Tuccori, M
Bleeding Related to Oral Anticoagulant Drugs as Cause of Emergency Department Admission: Analysis of Data from the Tuscan MEREAFaPS Network
2015-01-01 Saporiti, A; Sansone, Ac; Mantarro, S; Convertino, I; Montagnani, S; Marino, A; Rossi, M; Moschini, M; Vannacci, A; Santini, M; Spisni, L; Blandizzi, C; Tuccori, M
Challenges of Pharmacovigilance in the Neonate
2016-01-01 Convertino, I; Sansone, Ac; Marino, A; Galiulo, Mt
Characterization of the Risk of Bleeding with Novel Oral Anticoagulants and Warfarin: A Pilot Case-Control Study
2014-01-01 Mantarro, S; Annoni, V; Garibaldi, D; Brubelleschi, G; Frosini, F; Blandizzi, C; Polimeni, J; Capogrosso-Sansone, A; Convertino, I; Montagnani, S; Saporiti, A; Ruggiero, E; Fazzi, B; Mazzarri, L; Fornai, M; Antonioli, L; Salvadori, S; Tuccori, M
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence
2017-01-01 Tuccori, Marco; Convertino, Irma; Galiulo, Maria Teresa; Marino, Alessandra; Capogrosso-Sansone, Alice; Blandizzi, Corrado
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy
2021-01-01 Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study
2021-01-01 Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G
Estimation of Theoretical Cost Preventability Achievable with an Effective Pharmacovigilance Activity in a Pharmacovigilance Regional Centre in Italy
2015-01-01 Tuccori, M; Convertino, I; Sansone, Ac; Mantarro, S; Marino, A; Montagnani, S; Saporiti, A; Blandizzi, C
Expected and actual adverse drug-drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study
2016-01-01 Marino, Alice; CAPOGROSSO SANSONE, Alice; Tuccori, Marco; Bini, Giacomo; Calsolaro, Valeria; Mantarro, Stefania; Convertino, Irma; Pasqualetti, Giuseppe; Orsitto, E.; Santini, Massimo; Monzani, Fabio; Blandizzi, Corrado
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A clinician network for sharing patients experiences in pharmacovigilance: the PHARMACOWIKILANCE project | 1-gen-2017 | Convertino, I; Galiulo, M; Sansone, Ac; Marino, A; Knezevic, T; Pieroni, S; Blandizzi, C; Tuccori, M | |
| A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy | 1-gen-2018 | Convertino, I; Salvadori, S; Pecori, A; Galiulo, Mt; Ferraro, S; Parrilli, M; Corona, T; Turchetti, G; Blandizzi, C; Tuccori, M | |
| Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) | 1-gen-2021 | Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M | |
| Adverse drug reactions in oncoLogy: intEnsive monitoring program on biotechnological anD taRget therapies in Oncologic patientS-ALEXANDROS observational study | 1-gen-2017 | Galiulo, M; Convertino, I; Blandizzi, C; Tassi, R; Diacciati, S; Nobili, S; Sansone, Ac; Marino, Aa; Mini, E; Mazzei, T; Vannacci, A; Parrilli, M; Corona, T; Tuccori, M | |
| Allopurinol adherence among patients with gout: an Italian general practice database study | 1-gen-2015 | Mantarro, Stefania; CAPOGROSSO SANSONE, Alice; Tuccori, Marco; Blandizzi, Corrado; Montagnani, S; Convertino, I; Antonioli, Luca; Fornai, Matteo; Cricelli, I; Pecchioli, S; Cricelli, C; Lapi, F. | |
| An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future | 1-gen-2021 | Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D. | |
| Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) | 1-gen-2021 | Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M. | |
| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline | 1-gen-2020 | Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D. | |
| Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease | 1-gen-2019 | Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I | |
| Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports | 1-gen-2019 | Ferraro, S; Leonardi, L; Blandizzi, C; Convertino, I; Tuccori, M | |
| Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study | 1-gen-2019 | Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Salvadori, S; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Riengler, S; Menditto, E; Parrilli, M; Rossi, M; Orlando, V; Pieroni, S; Vannacci, A | |
| Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study | 1-gen-2018 | Ferraro, S; Convertino, I; Salvadori, S; Pieroni, S; Pecori, A; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Parrilli, M; Rossi, M; Vannacci, A; Blandizzi, C; Tuccori, M | |
| Bleeding Related to Oral Anticoagulant Drugs as Cause of Emergency Department Admission: Analysis of Data from the Tuscan MEREAFaPS Network | 1-gen-2015 | Saporiti, A; Sansone, Ac; Mantarro, S; Convertino, I; Montagnani, S; Marino, A; Rossi, M; Moschini, M; Vannacci, A; Santini, M; Spisni, L; Blandizzi, C; Tuccori, M | |
| Challenges of Pharmacovigilance in the Neonate | 1-gen-2016 | Convertino, I; Sansone, Ac; Marino, A; Galiulo, Mt | |
| Characterization of the Risk of Bleeding with Novel Oral Anticoagulants and Warfarin: A Pilot Case-Control Study | 1-gen-2014 | Mantarro, S; Annoni, V; Garibaldi, D; Brubelleschi, G; Frosini, F; Blandizzi, C; Polimeni, J; Capogrosso-Sansone, A; Convertino, I; Montagnani, S; Saporiti, A; Ruggiero, E; Fazzi, B; Mazzarri, L; Fornai, M; Antonioli, L; Salvadori, S; Tuccori, M | |
| Diabetes drugs and the incidence of solid cancers: a survey of the current evidence | 1-gen-2017 | Tuccori, Marco; Convertino, Irma; Galiulo, Maria Teresa; Marino, Alessandra; Capogrosso-Sansone, Alice; Blandizzi, Corrado | |
| Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy | 1-gen-2021 | Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M | |
| Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study | 1-gen-2021 | Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G | |
| Estimation of Theoretical Cost Preventability Achievable with an Effective Pharmacovigilance Activity in a Pharmacovigilance Regional Centre in Italy | 1-gen-2015 | Tuccori, M; Convertino, I; Sansone, Ac; Mantarro, S; Marino, A; Montagnani, S; Saporiti, A; Blandizzi, C | |
| Expected and actual adverse drug-drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study | 1-gen-2016 | Marino, Alice; CAPOGROSSO SANSONE, Alice; Tuccori, Marco; Bini, Giacomo; Calsolaro, Valeria; Mantarro, Stefania; Convertino, Irma; Pasqualetti, Giuseppe; Orsitto, E.; Santini, Massimo; Monzani, Fabio; Blandizzi, Corrado |